MedTrace Logo

Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

NCT03338387 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-02-19

No results posted yet for this study

Summary

This study evaluates the addition of Acipimox or placebo to exercise on growth hormone release and ghrelin secretion in bulimic patients and in healthy women. Two groups of participants will receive Acipimox together with exercise versus identical placebo with exercise.

Conditions

  • Eating Disorder
  • Bulimia Nervosa

Interventions

DRUG

Acipimox

Acipimox

DRUG

Placebo

Placebo Other Names: Placebo (for Olbetam)

Sponsors & Collaborators

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Kvido Smitka, M.D., Ph.D. · Charles University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-05-06
Primary Completion
2007-12-16
Completion
2026-12-20

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03338387 on ClinicalTrials.gov